Lymphovascular invasion is a significant predictor for distant recurrence in patients with early-stage endometrial endometrioid adenocarcinoma

Sharon Nofech-Mozes, Ida Ackerman, Zeina Ghorab, Nadia Ismiil, Gillian Thomas, Al Covens, Mahmoud A. Khalifa

Research output: Contribution to journalArticlepeer-review

31 Scopus citations

Abstract

To evaluate the value of lymphovascular invasion (LVI) in endometrial endometrioid adenocarcinoma (EEA) as a predictor for distant recurrence, we analyzed the histopathologic features of 513 consecutive cases of nonsurgically staged EEA limited to the uterus. Grade, myoinvasion, cervical involvement, and LVI were evaluated. With a median follow-up of 28 months (range, 2-144 months), 67 cases (13.1%) recurred, 37 (7.2%) had locoregional recurrence, and 30 (5.8%) developed distant recurrence. LVI was identified in 116 cases (22.6%) cases and was the only adverse histopathologic finding in 23 cases; 5 (22%) of the 23 recurred. Multivariate analysis demonstrated a significant association between any type of recurrence and cervical involvement (hazard ratio [HR], 2.760; 95% confidence interval [CI], 1.621-4.698) and LVI (HR, 2.717; CI, 1.568-4.707). Multivariate analysis revealed LVI as the only independent predictor for distant recurrence (HR, 2.841; CI, 1.282-6.297). Studies to examine the role of adjuvant systemic therapy in patients with early-stage disease should be considered.

Original languageEnglish (US)
Pages (from-to)912-917
Number of pages6
JournalAmerican journal of clinical pathology
Volume129
Issue number6
DOIs
StatePublished - Jun 2008

Keywords

  • Adjuvant therapy
  • Distant recurrence
  • Endometrial endometrioid adenocarcinoma
  • Lymphovascular invasion
  • Pathologic features
  • Prognosis

Fingerprint Dive into the research topics of 'Lymphovascular invasion is a significant predictor for distant recurrence in patients with early-stage endometrial endometrioid adenocarcinoma'. Together they form a unique fingerprint.

Cite this